Merlini, G
Lousada, I
Ando, Y
Dispenzieri, A
Gertz, M A
Grogan, M
Maurer, M S
Sanchorawala, V
Wechalekar, A
Palladini, G
Comenzo, R L
Article History
Received: 7 March 2016
Revised: 17 June 2016
Accepted: 4 July 2016
First Online: 15 July 2016
Competing interests
: GM has received honoraria from Millennium Takeda and Pfizer, consulting fees from Janssen, speaker fees from Pfizer and travel expenses from Janssen and Pfizer. IL has received speaker fees from Pfizer. AD has received grants from Celgene, Takeda, Pfizer and Alnylam, and travel expenses from Pfizer and Roche. MAG has received honoraria from Celgene, Novartis, Millennium, Med Learning Group, Research to Practice, Onyx, Isis Pharmaceuticals, Sanofi and Prothena; consulting/advisory fees from Prothena; and travel expenses from Prothena and Celgene Novartis. MG has received research support from Pfizer and Alnylam, and consulting/advisory fees and travel expenses from Prothena. MSM’s institution, Columbia University Medical Center, has received research funding and advisory board and DSMB fees from Pfizer, Alnylam Pharmaceuticals, ISIS Pharmaceuticals and Prothena. VS has received grants from Celgene, Takeda, Prothena and Onyx Pharmaceuticals. AW has received honoraria from Celgene and Takeda, advisory fees from GlaxoSmithKline and BPL, and research support (to department) from Amgen (Onyx) and Binding Site. GP has received travel expenses from Celgene. RLC has received consulting fees or honoraria from Takeda Millennium, Karyopharm, and Janssen and research support from Takeda Millennium, Prothena, Janssen, and Teva. YA declares no conflict of interest.